All In Biotech

Drug Trial Radar · NCT06340360

A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Very Severe Alopecia Areata in Adult Patients (Rezolve AA)

A Phase 2b, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rezpegaldesleukin in the Treatment of Severe to Very Severe Alopecia Areata in Adult Patients (Rezolve AA)

Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

94

Actual

Start

Apr 2, 2024

Primary completion

Nov 26, 2025

Study completion Aug 20, 2026

Sponsor

Lead sponsor
Nektar TherapeuticsIndustry
Sponsor type
Industry
First posted
Apr 1, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an interventional, randomized, double blind, parallel group, placebo-controlled, Phase 2b, 3-arm study to assess the effect of pegylated-recombinant-human interleukin-2 (rezpegaldesleukin) in adult participants with severe to very severe alopecia areata. The estimated duration includes a screening period of up to 35 days, a 36-week treatment period, an optional 16-week treatment extension period, and a 24-week follow-up period. The maximum study duration is approximately 81 weeks for all participants.

Conditions

  • Alopecia Areata

Interventions

  • RezpegaldesleukinDrug

    Pharmaceutical form: Injection solution Route of administration: subcutaneous

  • PlaceboDrug

    Pharmaceutical form: Injection solution Route of administration: subcutaneous

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent change from baseline in Severity of Alopecia Tool (SALT) score at Week 36Time frame: Baseline and Week 36

Locations

26 sites in 3 countries. Site status is shown where the registry gives one.

  • Nektar Investigative Site

    Northridge, California

  • Nektar Investigative Site

    Atlanta, Georgia

  • Nektar Investigative Site

    Gurnee, Illinois

  • Nektar Investigative Site

    Indianapolis, Indiana

  • Nektar Investigative Site

    Clinton Township, Michigan

  • Nektar Investigative Site

    Portsmouth, New Hampshire

  • Nektar Investigative Site

    New York, New York

  • Nektar Investigative Site

    Camp Hill, Pennsylvania

  • Nektar Investigative Site

    Frisco, Texas

  • Nektar Investigative Site

    Pflugerville, Texas

  • Nektar Investigative Site

    Surrey, British Columbia, Canada

  • Nektar Investigative Site

    Markham, Ontario, Canada

  • Nektar Investigative Site

    Oakville, Ontario, Canada

  • Nektar Investigative Site

    Richmond Hill, Ontario, Canada

  • Nektar Investigative Site

    Sherbrooke, Quebec, Canada

  • Nektar Investigative Site

    Wroclaw, Lower Silesian Voivodeship, Poland

  • Nektar Investigative Site

    Wroclaw, Lower Silesian Voivodeship, Poland

  • Nektar Investigative Site

    Wroclaw, Lower Silesian Voivodeship, Poland

  • Nektar Investigative Site

    Nowa Sól, Lubusz Voivodeship, Poland

  • Nektar Investigative Site

    Warsaw, Masovian Voivodeship, Poland

  • Nektar Investigative Site

    Warsaw, Masovian Voivodeship, Poland

  • Nektar Investigative Site

    Gdansk, Pomeranian Voivodeship, Poland

  • Nektar Investigative Site

    Katowice, Silesian Voivodeship, Poland

  • Nektar Investigative Site

    Sosnowiec, Silesian Voivodeship, Poland

  • Nektar Investigative Site

    Olsztyn, Warmian-Masurian Voivodeship, Poland

  • Nektar Investigative Site

    Szczecin, West Pomeranian Voivodeship, Poland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.